Phibio

Phibio is a South Korean biotechnology company specializing in the development of microbiome-based therapeutics, often referred to as "pharmabiotics." The company focuses on metabolic and inflammatory diseases by identifying and harnessing specific bacterial strains that modulate host physiology and immune responses. Its lead candidate, PB-101, is an oral live biotherapeutic product designed to treat obesity and type 2 diabetes by influencing metabolic pathways and the gut-brain axis. Phibio's pipeline also includes programs for non-alcoholic steatohepatitis (NASH/MASH) and atopic dermatitis, all derived from its proprietary microbial discovery platform. The company aims to translate microbiome science into standardized, clinical-grade treatments for chronic global health challenges.